Advanced search
Publication Cover
Infectious Diseases Volume 50, 2018 - Issue 3
Submit an article Journal homepage
319
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

The use of cefepime as a carbapenem-sparing antibiotic for treating uncomplicated acute pyelonephritis caused by extended-spectrum β-lactamase producing Escherichia coli

Jin Woong SuhDepartment of Internal Medicine, Division of Infectious Diseases, Korea University College of Medicine, Seoul, Republic of Korea; View further author information
,
Kyung Sook YangDepartment of Biostatistics, Korea University College of Medicine, Seoul, Republic of KoreaView further author information
,
Sun Bean KimDepartment of Internal Medicine, Division of Infectious Diseases, Korea University College of Medicine, Seoul, Republic of Korea; View further author information
,
Jong Hun KimDepartment of Internal Medicine, Division of Infectious Diseases, Korea University College of Medicine, Seoul, Republic of Korea; View further author information
,
Jang Wook SohnDepartment of Internal Medicine, Division of Infectious Diseases, Korea University College of Medicine, Seoul, Republic of Korea; View further author information
,
Min Ja KimDepartment of Internal Medicine, Division of Infectious Diseases, Korea University College of Medicine, Seoul, Republic of Korea; View further author information
&
Young Kyung YoonDepartment of Internal Medicine, Division of Infectious Diseases, Korea University College of Medicine, Seoul, Republic of Korea; Correspondence[email protected]
View further author information
 show all
Pages 241-244 | Received 08 Aug 2017, Accepted 15 Oct 2017, Published online: 31 Oct 2017

References

  • Kernéis S, Valade S, Geri G, et al. Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Dis (Lond). 2015;47:789–795.
  • Lee NY, Lee CC, Huang WH, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2013;56:488–495.
  • Blanchette LM, Kuti JL, Nicolau DP, et al. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis. 2014;46:803–808.
  • Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57:781–788.
  • Wang R, Cosgrove SE, Tschudin-Sutter S, et al. Cefepime therapy for cefepime-susceptible extended-spectrum β-lactamase-producing enterobacteriaceae bacteremia. Open Forum Infect Dis. 2016;3:ofw132.
  • Park SH, Choi SM, Chang YK, et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014;69:2848–2856.
  • Harris PN, Wei JY, Shen AW, et al. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71:296–306.
  • Vardakas KZ, Tansarli GS, Rafailidis PI, et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–2803.
  • Siedner MJ, Galar A, Guzmán-Suarez BB, et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis. 2014;58:1554–1563.
  • Asakura T, Ikeda M, Nakamura A, et al. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2014;29:91–95.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.